03/31/2017

The FDA approved IBRANCE (palbociclib) for the treatment of specific types of breast cancer.

The FDA has granted regular approval to IBRANCE (palbociclib) for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women.

For more information, click here.